Generex, Amarantus in collaboration to treat pre-diabetes
This article was originally published in Scrip
Canadian biotech Generex and Amarantus BioSciences of Sunnyvale, California, have announced that they have selected a second programme for their joint research collaboration involving diabetes. The two will work on the development of a therapeutic utilising Amarantus' MANF proteins for the treatment of the beta cell destruction at the root of diabetes. Amarantus' MANF proteins mediate apoptosis throughout the body.